IP Library Granted Patent US 9,663,484
Granted Patent B2
US 9,663,484 · App. 13/881,609 · Granted May 30, 2017

Isoflavonoid compounds and methods for the treatment of cancer

Inventors: George Jeoffreys (Baulkham Hills, AU); Alison Johnson (Drummoyne, AU); Andrew Heaton (Alexandria, AU); Ofir Moreno (Poway, CA)
Assignee: MEI PHARMA, INC.
C07D311/58A61K9/0019A61K9/5161A61K31/337A61K31/353A61K31/555A61K33/24A61K45/06A61K47/40
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,663,484
App. No.
13/881,609
Granted
May 30, 2017
Kind
B2
Abstract

Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.

Claims (8)

1. A pharmaceutical composition comprising d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.

2. The composition of claim 1 , wherein the composition further comprises an anti-cancer agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, epirubicin, cyclophosphamide, capecitabine, 5-fluorouracil, vinorelbine, trastuzumab, or bevacizumab.

3. A kit comprising a composition comprising d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol; and a sealable, plastic infusion bag.

4. A method of treating cancer in an individual in need of cancer therapy, the method comprising administering to the individual a composition comprising d-cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.

5. The method of claim 4 , wherein the composition increases or induces sensitivity of the cancer to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

6. The method of claim 5 , wherein the cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

7. The method of claim 4 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, and cancers of the brain.

8. The method of claim 4 , wherein said cancer is human breast cancer or ovarian cancer.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 27, 2024
From: MEI PHARMA, INC
To: AARDVARK THERAPEUTICS, INC.
Reel/Frame 069422/0065 →
CHANGE OF NAME Recorded Apr 6, 2016
From: MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 038366/0198 →
Continuity (2)
Provisional Application 61408972 · Nov 1, 2010
Related Publication 20140234295A1 · Aug 21, 2014